These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 23617284)

  • 1. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
    Cheng H; Qin Q; Sun X; Li F; Sun N; Cheng L; Lu Z; Chen B
    Technol Cancer Res Treat; 2013 Oct; 12(5):473-82. PubMed ID: 23617284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
    Li XD; Han JC; Zhang YJ; Li HB; Wu XY
    Asian Pac J Cancer Prev; 2013; 14(1):145-8. PubMed ID: 23534713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
    Li P; Wang YD; Cheng J; Chen JC; Ha MW
    Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
    Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Feng J; Sun X; Sun N; Qin S; Li F; Cheng H; Chen B; Cao Y; Ma J; Cheng L; Lu Z; Ji J; Zhou Y
    Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):429-35. PubMed ID: 19430706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
    Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
    Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
    Santarpia M; Ramirez JL; de Aguirre I; Garrido P; Pérez Cano M; Queralt C; Gonzalez-Larriba JL; Insa A; Provencio M; Isla D; Camps C; Blanco R; Moran T; Rosell R;
    Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.
    Wu W; Li H; Wang H; Zhao X; Gao Z; Qiao R; Zhang W; Qian J; Wang J; Chen H; Wei Q; Han B; Lu D
    PLoS One; 2012; 7(3):e33200. PubMed ID: 22479369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
    Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
    Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
    Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
    Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
    Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
    J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
    Li Y; Huang XE; Jin GF; Shen HB; Xu L
    Asian Pac J Cancer Prev; 2011; 12(3):739-42. PubMed ID: 21627375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
    Chen X; Zhang L; Ren S; Li X; Zhou F; Li W; Gao G; He Y; Zhou C
    Med Oncol; 2014 Apr; 31(4):865. PubMed ID: 24535606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
    Li X; Shao M; Wang S; Zhao X; Chen H; Qian J; Song X; Wang J; Jin L; Wu J; Li Q; Bai C; Han B; Gao Z; Lu D
    Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Zhang XR; Xu BH; Lin DX
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):196-9. PubMed ID: 16875604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.